Aptose Biosciences, Inc.
APTO
APTO was delisted on the 1st of April, 2025.
31 hedge funds and large institutions have $29.6M invested in Aptose Biosciences, Inc. in 2019 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 12 increasing their positions, 4 reducing their positions, and 7 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 4
14% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 7
3% more funds holding
Funds holding: 30 → 31 (+1)
5% less capital invested
Capital invested by funds: $31.1M → $29.6M (-$1.54M)
99% less call options, than puts
Call options by funds: $2K | Put options by funds: $251K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$2.16M |
| 2 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$1.82M |
| 3 |
PAWC
P.A.W. Capital
Greenwich,
Connecticut
|
+$1.26M |
| 4 |
Man Group
London,
United Kingdom
|
+$323K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$215K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DS
DRW Securities
Chicago,
Illinois
|
-$471K |
| 2 |
PVI
Pura Vida Investments
New York
|
-$392K |
| 3 |
Squarepoint
New York
|
-$78K |
| 4 |
VF
Virtu Financial
New York
|
-$58.1K |
| 5 |
Renaissance Technologies
New York
|
-$56K |
APTO Hedge Fund Activity: Q3 2019 in Review
31 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Aptose Biosciences, Inc. (APTO) for Q3 2019, worth a combined $29.6M — down 5% from $31.1M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new APTO positions and 7 closed out — a net gain of 1 holder — while 12 added to existing stakes and 4 trimmed.
The largest buyer was Nantahala Capital Management, adding an estimated $2.16M. The largest seller was DRW Securities, cutting an estimated $471K.
- 31 institutional investors held Aptose Biosciences, Inc. (APTO) as of Q3 2019, up from 30 in Q2 2019.
- Funds reported $29.6M of Aptose Biosciences, Inc. stock for Q3 2019, down 5% quarter-over-quarter.
- 8 funds opened new Aptose Biosciences, Inc. positions in Q3 2019 and 7 closed out, a net change of +1 holder.
- The largest Aptose Biosciences, Inc. buyer in Q3 2019 was Nantahala Capital Management, an estimated $2.16M added.
- The largest Aptose Biosciences, Inc. seller in Q3 2019 was DRW Securities, an estimated $471K sold.
Based on aggregated 13F filings for Q3 2019.